Here's why the Paragon (ASX:PGC) share price has surged 19% today

The Paragon Care Ltd (ASX: PGC) share price is soaring today following updates of the company's debt financing and third quarter performance.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paragon Care Ltd (ASX: PGC) share price is flying today following two exciting updates from the company. At the time of writing, the Paragon share price is 19% higher than its previous close, with shares in the company trading for 25 cents.

This comes after Paragon announced that it had renegotiated its financing facilities with the National Australia Bank Ltd (ASX: NAB). It also provided the market with a positive update to its quarterly performance.

Let's take a closer look at today's news from the medical device company.

Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

Renegotiated financing facilities

Paragon announced today it has renegotiated its financing facilities with NAB.

The company expects the new banking facility to create $575,000 of savings annually, increasing in time.

The new banking contract will cover the next 3 years and is designed to support the company's future growth.

Paragon states the new facility will allow it to resume dividends and explore acquisition opportunities.

As of the end of March, Paragon had $101 million in debt. Its amortisation will resume from 1 July 2021.

Paragon's third quarter update

Paragon also announced today its earnings before interest, tax, depreciation, and amortisation (EBITDA) for the financial year to date at the end of last quarter was 79% higher than the prior corresponding period.

It said its improved performance reflects its new cost rationalisation program, which has significantly reduced its employment, marketing, and administration costs.

Paragon also stated its trading conditions have improved over the past six months. Particularly, elective surgery has now returned to pre-COVID levels. As a backlog of elective surgery cases still remain, sustained demand of the company's devices is expected to continue until next year.  

Paragon's revenue for the financial year to date is down 3% compared to the prior corresponding period. It's raked in $173 million so far. Its gross profits are in line with the prior corresponding period.

The company also made $15.3 million in payments to vendors for business acquisitions this financial year. It now has no more payments remaining. Paragon states this will lead to significantly more free cash flow in the future.

As of 31 March 2021, the company had $19 million in cash.

Commentary from management

Paragon's CEO Phil Nicholl commented today's updates, saying:

The successful renegotiation of our banking facilities is a significant milestone for the Company. The strength of our underlying business now means that we can repay debt, whilst also preserving our ability to pay dividends and explore acquisition opportunities…

Over the past year, we have been working hard to implement improved processes across the business and these initiatives are now delivering over $7 million in annualised savings and a structurally lower cost base… We are well positioned to capitalise on the growth opportunities to expand our market share as COVID pressure abates.

Paragon Care share price snapshot

The boost to the Paragon Care share price from today's news has put the company's shares back into the green on the ASX.

Currently, the Paragon share price is up 8.7% year to date. It's also gained 25% over the last 12 months.

The company has a market capitalisation of around $70 million, with approximately 337 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
BNPL shares

Are Zip shares still a buy after soaring 20%

Zip shares are now 67% higher than this time 12 months ago.

Read more »

A male ASX 200 broker wearing a blue shirt and black tie holds one hand to his chin with the other arm crossed across his body as he watches stock prices on a digital screen while deep in thought
Share Market News

5 things to watch on the ASX 200 on Thursday

Here's what to expect on the local market today.

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

a group of business people sit dejectedly around a table, each expressing desolation, sadness and disappointment by holding their head in their hands, casting their gazes down and looking very glum.
Share Fallers

DroneShield shares tumble 17% as CEO exit revives leadership fears

Investors bank gains as DroneShield leadership reset unsettles sentiment...

Read more »

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Domino's and Pro Medicus shares

A leading analyst expects Domino’s and Pro Medicus shares to keep underperforming.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Coles, Endeavour, and Rio Tinto shares

The team at Morgans has given its verdict on these popular shares.

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Broker Notes

Morgans names two ASX 200 shares to buy and one to sell this week

Let's see which shares Morgans is bullish and bearish on this week.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Broker Notes

Why beaten down CSL shares now offer 'long-term appeal'

A leading expert gives his outlook for CSL’s beaten down shares.

Read more »